Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers
View Transcript. pdf icon[PDF – 165 KB] The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
Influenza remains a serious threat to children due to its potential to cause severe illness and death. Nearly 200 flu-associated deaths in children were reported to Centers for Disease Control and Prevention (CDC) during the 2019–2020 influenza season. Clinicians play a critical role in immunizing children, the children’s family members and caregivers, and themselves. While early use of antiviral drugs in children can reduce the duration of symptoms and prevent serious complications, immunization remains the most effective way to prevent influenza and its complications, including death. Immunization is particularly important during the severe COVID-19 pandemic.
During this COCA call, subject matter experts from the American Academy of Pediatrics (AAP) and CDC will discuss strategies primary care providers and medical subspecialists can use to improve flu prevention and control in children this season.
Fatimah Dawood, MD
Epidemiology and Prevention Branch
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Anne Kimball, MD, MPH
Maternal Child Health Unit
Centers for Disease Control and Prevention
Flor Munoz, MD, MSc, FAAP
Associate Professor of Pediatrics, Infectious Diseases, and Molecular Virology and Microbiology
Baylor College of Medicine
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Thursday, October 8, 2020,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
US: +16692545252,,1616039348# or +16468287666,,1616039348#
Webinar ID: 161 603 9348Add to Calendar
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention.”
Advanced registration is not required.
Date: Thursday, October 8, 2020
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 161 603 9348
Dial-in US: +1 669 254 5252 or +1 646 828 7666
iPhone one-tap: US: +16692545252,,1616039348# or +16468287666,,1616039348#
International numbers available: https://www.zoomgov.com/u/acuLtiwXKpexternal icon
At the conclusion of the session, the participant will be able to accomplish the following—
- Review data from the 2019-2020 U.S. influenza season to inform preparations for the 2020–2021 U.S. influenza season.
- Highlight key recommendations in the AAP influenza policy statement, “Recommendations for Prevention and Control of Influenza in Children, 2020–2021” and in CDC’s Advisory Committee on Immunization Practices’ document, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2020–21 Influenza Season.”
- Discuss the importance of vaccinating, testing, and treating influenza during the COVID-19 pandemic.
- Review recommendations about influenza antiviral use in children.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.
To receive continuing education (CE) for WC2922-100820—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers, Thursday, October 8, 2020, please visit TCEO and follow these 9 Simple Steps by Monday, November 9, 2020.
To receive continuing education (CE) for WD2922-100820—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers, Tuesday, November 10, 2020, (Web on Demand), please visit TCEO and follow these 9 Simple Steps by Thursday, November 10, 2022.
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-20-051-L04-P and enduring JA4008229-0000-20-052-H04-P course category.
This activity has been designated as Knowledge-Based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Munoz, and she would like to disclosure that she received a royalty for writing the Influenza chapter in the book Up to Date, and that she received research grants from industry (Biocryst, Gilead, Janssen) to study respiratory viruses, epidemiology, prevention, treatment strategies.
Planning committee reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use, with the exception of Drs. Dawood and Munoz who may discuss Neuraminidase inhibitor medications (antivirals) which are FDA approved only for the treatment of uncomplicated influenza; however, they will discuss off-label use such as for hospitalized patients and ages not FDA-approved. They may also discuss the investigational use of other influenza antiviral agents such as Baloxivir. Dr. Munoz would like to disclosure that she will discuss how antivirals for influenza are not licensed specifically for high risk, hospitalized patients; however, CDC and AAP recommend them for this population. Influenza vaccine is not licensed specifically for pregnant women; however, CDC, ACOG and AAP recommend it.
CDC did not accept commercial support for this continuing education activity.
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.